A new £13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland was launched by Enterprise Minister Arlene Foster MLA on Wednesday 4 September 2013.

As part of the project, Queen’s and Almac Discovery have announced the scheduling of a phase one clinical trial for ovarian cancer, involving the first novel cancer drug fully developed in Northern Ireland. Involving up to 60 ovarian cancer patients, the drug being trialled has been created as a result of an earlier collaboration between Almac Discovery and Professor Tracy Robson from the School of Pharmacy at Queen’s.

Explaining about the trial, Professor Robson said: “This latest trial involves a new treatment for cancer known as ALM201, which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients and thereby preventing their growth. It targets tumours by an entirely different pathway to those treatments currently approved.”

Alan Armstrong, CEO of Almac added: “Bringing new treatments to patients is a complex process. The announcement of this new clinical trial, which is the result of a previous partnership between Almac and Queen’s School of Pharmacy, is a timely illustration of how collaboration between the University and industry is already creating novel approaches to cancer therapy which have a very real chance of helping patients.”

Enterprise Minister Arlene Foster, said: “This significant investment in research and development will enhance collaboration between academia and industry. This will ensure the investment is maximised, that research is effectively commercialised and that ultimately, enhanced treatment solutions are made available to cancer patients.”

It was also announced that a new CCRCB/Almac Discovery joint programme in Cancer Drug Discovery will bring researchers from Queen’s University Belfast’s Centre for Cancer Research and Cell Biology (CCRCB) and scientists from Almac Discovery together to translate research discoveries into treatments for patients.

The two projects represent a total investment of £13M, with £7 million of support offered by Invest Northern Ireland, which includes part funding from the European Regional Development Fund. As a result of the joint programme, 17 scientists from Almac Discovery have been seconded to Queen’s CCRCB in an industry led venture. The discovery team will work to identify parts of tumours which are susceptible to treatment by cancer drugs and to then develop the new drugs to target them. The partnership will also enable new approaches to selecting those patients who will be most likely to respond to the new drugs, and to create the technologies needed to deliver the drugs directly to the tumour site in the patient.

The new discovery programme is being led by Professor Tim Harrison, Vice President of Discovery Chemistry with Almac Discovery. As part of this partnership, Professor Harrison has been appointed McClay Chair of Medicinal Chemistry at Queen’s for the next three years. Commenting on the new partnership, he said: “While Almac Discovery and Queen’s have already been successfully collaborating for a number of years, this exciting new programme is bringing together for the first time, under one roof, some of our most talented scientists. As a result we expect to see an increase in both the breadth of drug targets we are able to identify and a subsequent increase in the development of potential therapeutics for patients.”
Ulster Rugby has partnered with Cancer Research UK as their charity of the year for this season, and the partnership, which aims to ‘Kick Cancer Into Touch’, was launched at the CCRCB on 28 August 2013. Thirty Ulster Rugby players, management and staff were welcomed to the CCRCB by Professor David Waugh and had a tour of the labs. The players met the medical research staff and were able to hear at first-hand about the research within the labs in CCRCB. The President of Ulster Rugby, John Robinson, said: “Ulster Rugby is totally committed to this partnership as we feel it is very important to contribute as fully as we can to this charity which strives to overcome this awful disease that affects so many people in Ulster and further afield.”

The partnership aims to raise over £20,000 throughout the course of the season. Four match day collections will be held at Ravenhill and four fundraising events will be staged over the course of the year.
REPORT FROM THE 4TH INTERNATIONAL CONFERENCE IN ‘QUANTITATIVE BIOLOGY AND BIOINFORMATICS IN MODERN MEDICINE’

From 19-20 September 2013, 14 speakers from 5 countries gathered at the beautiful Riddel Hall in Belfast to present the newest findings of their research.

After the welcome address, provided by Professor Patrick Johnston, the keynote lecture with the title ‘Modeling Endocrine Resistance in Breast Cancer’ was presented by Robert Clarke from the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (USA). Interestingly, the common theme that emerged from all the different talks presented during the 2-day meeting was the realization that complex diseases like breast cancer can only be understood with a systems approach, casting the shadows of genomic and systems medicine. This culminated in the talk given by Sol Efroni, from The Mina and Everard Faculty of Life Science, Bar Ilan University (Israel), with the intriguing title ‘The Network is a Biomarker in Cancer Signatures.’

Frank Emmert-Streib said: “We are proud that we were able to organize this conference for the fourth consecutive year. Initially started from funding provided by the Department for Employment and Learning through its “Strengthening the all-Island Research Base” initiative, which ended a couple of years ago, the conference is its living legacy, and we would like to thank everyone who helped us to make this a sustainable event.”

The organizers of the conference, Frank Emmert-Streib, Peter Hamilton and Shu-Dong Zhang, would like to congratulate the winners of this year’s poster competition, Fabio Liberante and Qing Wen, for their valued contribution.

BRCA LINK NI INFORMATION DAY

Cancer researchers from Queen’s University hosted an information day on Friday 25 October for patients who are BRCA gene mutation carriers, and for those who wanted to find out more about hereditary cancers.

Held in conjunction with BRCA Link NI, a voluntary organisation raising awareness of hereditary breast and ovarian cancer, the event was open to people affected by the BRCA1 and BRCA2 genes, which increase susceptibility to breast and ovarian cancer in carriers. The event was a great success, with around 70 people attending with their families.

The keynote speaker was Wendy Watson, who told her inspirational story. Wendy fought in the early 1990’s to convince her GP that some breast cancers might be hereditary (both her mother and grandmother had died from breast cancer). She convinced her doctors that a prophylactic double mastectomy was the best course of action in risk reduction when there was no scientific backup. This is now the recommended treatment option for BRCA mutation carriers. Wendy instigated the first hereditary breast cancer awareness week and has raised millions for improved management of hereditary breast cancer patients. She now runs the Hereditary Breast Cancer Helpline and sits on numerous government bodies advising on the area.

The event also incorporated talks about a new high risk screening clinic based in Antrim Hospital as well as a new BRCA clinic in Belfast City Hospital. Those attending the information day also had a lab tour and took part in a ‘Meet the Expert’ session, where attendees could ask a panel of geneticists, surgeons, obs/gynae experts, oncologists and breast clinicians questions that were important to them.

Finally Professor Paul Harkin led a tribute to Dr Jennifer Quinn-O’Brien’s research into the area and how she has had such an immense impact on the field.

Further information is available online at www.brcani.co.uk.

The annual ‘Wear it Pink’ Coffee Morning was also held on the Information Day and was a great success, raising £445.40 (£550 including Gift Aid) for Breast Cancer Campaign.
As part of breast cancer awareness month, Cancer Focus Northern Ireland asked local women to host a Girls’ Night In during October to raise funds for pioneering breast cancer research at Queen’s University Belfast.

Cancer Focus, the new name for Ulster Cancer Foundation, promotes and supports internationally competitive, high quality research into the causes, treatment and prevention of cancer. Currently the charity is funding a research fellowship at CCRCB that is focusing on the prevention and treatment of breast cancer.

Roisin Foster, Cancer Focus Chief Executive, said: “Research is an extremely important element of what we do. Each year we invest £300,000 - £400,000 in cancer research to help identify the causes of cancer and discover improved methods of diagnosis and treatment. Many cancers previously thought to be incurable are now being treated successfully as a result of scientific research.”

Dr Kienan Savage, who received a Cancer Focus NI Fellowship, has recently identified a number of new cancer genes that appear to be involved in the development of breast and ovarian cancers, and some forms of leukaemia.

“These cancers often arise due to damage to genes within our DNA, known as ‘gatekeeper’ genes. The genes control how often cells divide, allowing cells to grow out of control forming a tumour. The new cancer genes which have been discovered appear to play a role in repairing damage to DNA and thereby aid the repair of damaged ‘gatekeeper’ genes, helping to prevent cancer,” Dr Savage said.

“My research will add significantly to our understanding of how these genes work to prevent the development of cancer. It may also lead to the development of new quick and effective tests to help decide which treatments specific cancer patients will benefit from, and may help to identify new proteins that could be targeted for future therapies. It’s fantastic to get this opportunity to develop my own independent research which has the potential to be hugely significant for cancer patients everywhere.”
NEW CRUK RESEARCH ENGAGEMENT MANAGER – MARGARET CARR

Margaret Carr, Belfast CRUK Research Engagement Manager

Margaret joined us as the Belfast Cancer Research UK Centre’s new Research Engagement Manager at the beginning of August.

As the Belfast Research Engagement Manager, Margaret’s role is to engage a wide range of people in Belfast and across Northern Ireland with the research taking place in their community. Audiences include people affected by cancer and their families, CRUK supporters, politicians and journalists, as well as the general public.

Margaret engages these different audiences in a variety of ways, arranging talks about CRUK funded clinical and lab-based research and bringing the research to life through interactive tours of the labs in the CCRCB. Research engagement also means finding opportunities for researchers to go out and speak about their work at community events in order to reach more people and build greater support for the pioneering research taking place here at the Centre.

Teachers and students are also a vital audience for the Centre, which has a clear commitment to hosting events and activities that inspire the next generation of cancer researchers. Margaret will be working with colleagues in the CCRCB to expand the annual teachers’ and schools’ days, and to develop the new schools’ competition, which launched for the first time this year.

Margaret also works closely with the press teams at CRUK and the other Centre partners to ensure that exciting new research developments make the news and raise the profile of the Centre.

Margaret will also be instrumental in keeping the central CRUK Policy team up to date on issues in Northern Ireland affecting cancer research, diagnosis and treatment, such as early diagnosis, research funding and regulation and radiotherapy provision. She will work with local politicians, statutory health bodies and others to promote CRUK’s policies on these issues.

Before joining us, Margaret was most recently Engagement Officer for Age NI, working with older people’s groups across Northern Ireland to widen and strengthen their input into consultations on health and social care. Prior to that, Margaret was Fair Trade Manager for Oxfam Ireland for 12 years.

To contact Margaret or find out more about her role email: margaret.carr@cancer.org.uk or call: 028 9097 2715.

INAUGURAL CRUK PATIENT ENGAGEMENT EVENT

On 6 September 2013, the first Cancer Research UK Patient Engagement event was held simultaneously at 10 Centres across the UK.

The event in Belfast was the first to reach its attendance capacity, and 30 cancer patients, survivors and family members attended the full day workshop. The aim of the day was to seek input as to how CRUK research, information, advocacy and engagement work should reflect the views and needs of people affected by cancer, and to get them involved in CRUK’s work.

The day included small group discussion sessions on patient involvement in CRUK research and the work of CRUK campaign ambassadors, and a presentation by Professor David Waugh on the work of the Centre. Regular Tweets from all the participating Centres throughout the day ensured there was lively cross-centre engagement on the day’s discussions, and the day ended with a live simulcast to all 10 participating Centres from Dr Harpal Kumar, CRUK’s Chief Executive.

Dr Sandra Irvine, one of the facilitators for the CRUK Patient Engagement event, in discussions with her group.
The EPOCAN Consortium, funded by an FP7 grant from the European Commission, held a Workshop at Queen’s on 7 and 8 October 2013, attended by 30 leading investigators drawn from universities and SMEs in Switzerland, Germany, Spain, the Netherlands, Austria, the UK and Israel.

Erythropoietin (EPO) is the hormone that controls red blood cell production, and is used to treat anaemia. The intention of the European collaboration is to determine whether EPO treatment is suitable for all cancer patients who suffer from the very debilitating effects of anaemia due to their chemotherapy treatment, or whether it should be restricted to certain individuals.

Mr Allister Murphy, a member of the NICRCF commented: “From a cancer patient perspective I was amazed to see the huge advances that have been made in radiotherapy technology in only a few years. The influence of research is clearly evident in every aspect of radiotherapy development and credit must go to the research teams and the patients who volunteer. Events like this help the public see the tangible benefits of research.”

QUEEN’S HOSTS WORKSHOP ON THE USE OF EPO IN THE TREATMENT OF ANAEMIA IN CANCER PATIENTS

CANCER RESEARCH WITH THE X-FACTOR!

‘Cancer Research with the X-Factor’ was a public information event hosted by the NI Cancer Research Consumer Forum (NICRCF) on 16 October 2013, to help raise awareness about the work of researchers and staff, working in radiotherapy, and fervently committed to driving advances in cancer care through research.

The audience gathered in the Cancer Centre, Belfast City Hospital, and the Chair of the NICRCF, Margaret Grayson, opened the evening by describing the role of Personal and Public Involvement in cancer research. The audience listened with fascination as Investigators described how research-driven innovations in radiotherapy and radionuclide treatments had led to faster availability of more effective treatment for patients in Northern Ireland. Research was a vital quality driver, and hence core to a high quality health service. Current research included delivery of higher radiotherapy doses tightly targeted to the cancer, while minimising radiation to surrounding tissue. This had several potential benefits; increased chance of curing cancer, decreased side-effects and reduced treatment visits.

A key to the success of the research strategy was a multi-professional approach, involving close collaboration of experts in clinical radiotherapy, radiation science and physics, within BHSCT and the Centre for Cancer Research and Cell Biology, QUB. The NI Cancer Trials Centre and research funders were also thanked, including Cancer Research UK, Friends of the Cancer Centre, HSC Research and Development Division and Movember.

Mr Allister Murphy, a member of the NICRCF commented: “From a cancer patient perspective I was amazed to see the huge advances that have been made in radiotherapy technology in only a few years. The influence of research is clearly evident in every aspect of radiotherapy development and credit must go to the research teams and the patients who volunteer. Events like this help the public see the tangible benefits of research.”

EPOCAN SEMINAR TALKS

As part of the EPOCAN Workshop held at CCRCB on Tuesday 8 October 2013, two of the group members, Dr John Thompson from Aldevron Freiburg GmbH and Professor Thomas Rülicke from the University of Veterinary Medicine in Vienna, gave seminar talks. Dr Thompson and Professor Rülicke are pictured with Professor Terry Lappin.
Congratulations to Dr Aidan Cole who has received this year’s St Luke’s Medal for the best clinical radiotherapy research project in Ireland.

The medal was awarded for his study investigating radiobiological modelling and dose escalation in lung cancer, following the introduction of 4D-CT scanning in the Northern Ireland Cancer Centre. Dr Cole was presented with his medal by Professor Phillip M. Devlin from the Dana-Farber Cancer Institute on 28 September 2013 at the Royal College of Surgeons in Dublin.

Congratulations to Professor Richard Kennedy who was named the winner of the Vice-Chancellor’s Impact Prize at an awards ceremony on Friday 15 November 2013. Professor Kennedy and his team have developed tests to personalise cancer treatment worldwide.

Dr Karl Butterworth won a National Institute of Health funded Scholarship to attend the 22nd annual course on Experimental Models of Human Cancer at the Jackson Laboratory, Bar Harbour, ME.

Dr Karl Butterworth won a Cancéropôles Grand Ouest travel award to speak at the 7th annual meeting on the Future of Radiation Oncology in Berder Island, Brittany, France.

PhD student Miss Gemma Logan won the prize for the best oral presentation at the Haematology Association of Ireland Annual Meeting.

It was announced at the Haematology Association of Ireland Annual Meeting on Friday 18 October 2013 that Dr Lisa Crawford won the Haematology Association of Ireland/The Royal College of Pathologists Research Fellowship Award for 2014. The award is for €20,000 and the title is ‘Defining new ubiquitin proteasome system targets in Multiple Myeloma’. The award will further the work on the Ubiquitin Proteasome System, which is carried out in collaboration with Professor Brian Walker, School of Pharmacy and Dr Mary Drake, Belfast Health and Social Care Trust.

Dr Karl Butterworth from the radiation biology group has been taking an international lead in developing initiatives for young scientists in the radiation sciences.

At the US Radiation Research Society annual meeting in New Orleans, Karl took up his position as Chair of the Scholars-in-training Committee of the Radiation Research Society. He now leads an international committee of 10 young investigators, representing the interests of over 400 Scholars-in-Training within the top International Radiation Research Society (www.radres.org). Within Europe, Karl has also been working with a group of scientists led by Dr Luca Marrioti from the University of Pavia, Italy, (who is a previous visiting researcher from the Radiation Biology Group at CCRCB) to establish a similar initiative for European Radiation Research Scientists called EURays. This seeks to provide support and sustainability for young scientists in the radiation research field in Europe. Details can be found at www.eurays.eu.

The initiative was recently launched at the annual European Low Dose Programme meeting. EU funded research in low dose radiation protection is being coordinated by a platform called the Multidisciplinary European Low Dose Initiative (MELODI). Queen’s University Belfast recently became an official member of the MELODI platform.

Mr Ryan Hutchinson, PhD student:
• presented a webinar for the Moffitt Cancer Centre, Tampa, Florida, USA (July 2013)
• won a Pathological Society Travel Award (September 2013)
• gave a Poster Presentation at ASCP (CCRCB/Cardiff University and MRC)
• won a Pathology Visions Speaker Award (September/October 2013)
• was 1 of 30 people selected to attend a Genomics Workshop at ASCP (Certificate awarded)
• was a Workshop Co-Presenter with Dr Charles Frevert (University of Washington) and Adam Smith (Merck Seron) (Pathology Visions 2013)
• was a Round-table Co-Chair with Dr Charles Frevert (Pathology Visions 2013)
• gave Poster Presentations at Pathology Visions (CCRCB/Janssen and CCRCB/Northern Ireland State Pathologist’s Department).

Dr Karl Butterworth

Professor Kevin Prise who will represent the University in MELODI said: “Our membership is testament to our strong radiation science program and puts us at the heart of the future European strategy for Low Dose Radiation Research.”
SECOND SUMMER SCHOOL IN COMPUTATIONAL BIOLOGY

This year the second summer school in Computational Biology took place from 16-18 September 2013.

The meeting gathered 25 students from 5 countries, making it the largest summer school so far. During 3 intense days, 18 lectures were provided by 10 instructors, covering topics from introductory lectures for the statistical programming language R, microarray and next-generation sequencing (NGS) data to advanced analysis methods, including clustering, classification and survival analysis.

The underlying theme of this year’s summer school was the importance of reproducible research. In this respect, the key role of the statistical programming language R was discussed as a natural and efficient mediator between data, analysis methods and the conservation of the whole analysis process in a way that allows an error-free exchange/communication of a conducted analysis.

As a highlight of the summer school Benjamin Haibe-Kains, from the Institut de Recherches Cliniques de Montreal (Canada), was invited to give a talk entitled ‘Significance Analysis of Prognostic Signatures.’ This allowed the students to ‘see’ the translation of analysis methods into clinical practice, which helped to realize the importance of computational biology. Frank Emmert-Streib said: “We are pleased to see the increased interest in the summer school, because it forms an integral part for the education of students at Queen’s, together with the newly established MSc in Computational Biology and the Conference in Quantitative Biology and Bioinformatics in Modern Medicine.” The third summer school in Computational Biology is anticipated to take place in September 2014.

LEUKAEMIA & LYMPHOMA NI

Have you seen the exciting changes taking place for Leukaemia & Lymphoma NI (previously known as Northern Ireland Leukaemia Research Fund) as we approach our 50th Anniversary in 2014? It’s not a change to the core of the charity, funding research into leukaemia and lymphoma - this will never change - but a new name and new look!

As the Northern Ireland Leukaemia Research Fund we have had a very proud history, 49 years’ experience and over £9 million spent supporting leukaemia and lymphoma research in Northern Ireland. As we look to our future, our primary focus remains to continue to fund life-saving research. On average 2 people in Northern Ireland are diagnosed every day with a blood cancer such as leukaemia, lymphoma or myeloma and we want that number to drop to zero.

We hope you will continue to join us on our new journey and help us spread the word about Leukaemia & Lymphoma NI!

To continue with our life-saving research we need to raise at least £500k every year. If you would like to support us or would like more information please email info@LeukaemiaAndLymphomaNI.org or see our new website: www.LeukaemiaAndLymphomaNI.org

NEW RESEARCH STUDENTS

<table>
<thead>
<tr>
<th>Students:</th>
<th>Supervisors:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Alderdice</td>
<td>Prof M Salto-Tellez &amp; Dr V Coyle</td>
</tr>
<tr>
<td>James Beirne</td>
<td>Dr P Mullan, Prof M Salto-Tellez &amp; Prof R Kennedy</td>
</tr>
<tr>
<td>Charlotte Burt</td>
<td>Prof K Mills &amp; Dr A Thompson</td>
</tr>
<tr>
<td>Catherine Davidson</td>
<td>Prof R Kennedy, Dr P Mullan &amp; Dr S Jain</td>
</tr>
<tr>
<td>Bailey Evans</td>
<td>Dr K McCloskey &amp; Prof R Kennedy</td>
</tr>
<tr>
<td>Nicholas Forsythe</td>
<td>Dr S Van Schaeybroeck &amp; Prof P Johnston</td>
</tr>
<tr>
<td>Jennifer Fox</td>
<td>Dr D Longley &amp; Dr C Scott</td>
</tr>
<tr>
<td>Dominique French</td>
<td>Dr S Jain &amp; Prof K Prise</td>
</tr>
<tr>
<td>Peter Gilliland</td>
<td>Dr R Williams &amp; Dr S Van Schaeybroeck</td>
</tr>
<tr>
<td>Ciara Lyons</td>
<td>Prof J O’Sullivan &amp; Prof D Waugh</td>
</tr>
<tr>
<td>Christopher McCann</td>
<td>Prof D Waugh &amp; Dr D Longley</td>
</tr>
<tr>
<td>Alexander McIntyre</td>
<td>Dr D Longley &amp; Dr S McDade</td>
</tr>
<tr>
<td>Benjamin Park</td>
<td>Prof M Lawler &amp; Prof P Johnston</td>
</tr>
<tr>
<td>Alexey Stupnikov</td>
<td>Dr F Emmert-Streib &amp; Prof M Salto-Tellez</td>
</tr>
<tr>
<td>Amy Templeman</td>
<td>Dr P Mullan &amp; Dr R Williams</td>
</tr>
<tr>
<td>Jekaterina Vohhodina</td>
<td>Prof P Harkin &amp; Dr K Savage</td>
</tr>
<tr>
<td>Emma Waring</td>
<td>Prof K Prise &amp; Dr A Kissenpfennig</td>
</tr>
</tbody>
</table>
PHOTO GALLERY

A group of work colleagues from CCRCB took ‘team work’ to an extreme and together participated in Queen’s University PEC’s Spinathon on 31 May 2013, raising a fantastic £3,250 for local charity Cancer Focus Northern Ireland. Five of the team kept spinning for the full 6 hour spin class! Pictured are Mihaela Ghita (Research Assistant), Dr Michael Moran (Clinical Research Fellow), Dr Susie Gray (Postdoctoral Research Fellow), Jacqueline McQuade (Spinathon Organiser) and Niamh McGivern (PhD Student).

On 18 August CCRCB post doctoral researcher Dr Keara Redmond put her fears behind her and rose to the challenge of a sponsored skydive to benefit the Cancer Research UK Newry fundraising committee. Keara along with twin sister Kelly raised a total of £1,118 through sponsorship from friends and family, some of which was raised from a coffee morning held in CCRCB.

Six CCRCB researchers joined with over 4,000 others in the first ever Belfast Colour Run. Runners in the 5K race through the Titanic Quarter had various bright coloured powders thrown at them at each kilometre. So the white t-shirts that started the race are definitely not white by the end! Kirsty McLaughlin and her sister Emma, Joel Riley, Naomi Dickson, Phil Burn, Jody Hay and Laura Kettyle ran in the August event which benefitted Stand Up to Cancer.

Professor David Waugh (Director, CCRCB) receiving a donation from Mr Raymond Mulligan for £530.
# RECENT GRANTS AWARDED

<table>
<thead>
<tr>
<th>Investigator(s)</th>
<th>Sponsor</th>
<th>Title</th>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emmert-Streib, Frank</td>
<td>Invest NI – PoC</td>
<td>Visualisation of Complex Networks</td>
<td>£102,507</td>
<td>01/01/14</td>
<td>31/12/14</td>
</tr>
<tr>
<td>Harkin, Paul</td>
<td>Invest NI – PoC</td>
<td>Novel Cancer Genes</td>
<td>£105,999</td>
<td>01/10/13</td>
<td>30/09/14</td>
</tr>
<tr>
<td>O’Sullivan, Joe</td>
<td>Friends of the Cancer Centre</td>
<td>Clinical Research Fellowship in Clinical Oncology</td>
<td>£180,000</td>
<td>01/01/14</td>
<td>31/12/16</td>
</tr>
<tr>
<td>Williams, Rich</td>
<td>PCUK</td>
<td>Development of a Legumain based Therapeutic for the Treatment of Prostate Cancer</td>
<td>£384,294</td>
<td>01/03/14</td>
<td>28/2/17</td>
</tr>
<tr>
<td>Prise, Kevin (PI Sandrine Lacombe, CNRS, Paris, France)</td>
<td>European Union FP7 Marie Curie Training Network</td>
<td>Advanced Radiotherapy, Generated by Exploiting Nanoprocesses and Technologies – ARGENT</td>
<td>€736,000 (of €7,500,000 grant)</td>
<td>01/03/14</td>
<td>30/09/17</td>
</tr>
<tr>
<td>Van Schaeybroeck, Sandra Johnston, Patrick Salto-Tellez, Manuel Wilson, Richard Kennedy, Richard Longley, Dan Lawler, Mark</td>
<td>EU</td>
<td>MErCuRIC</td>
<td>£265,322</td>
<td>01/10/14</td>
<td>30/09/19</td>
</tr>
<tr>
<td>Van Schaeybroeck, Sandra Johnston, Patrick</td>
<td>QUB Foundation</td>
<td>Tom Moran Studentship</td>
<td>£64,397</td>
<td>01/10/13</td>
<td>30/09/16</td>
</tr>
<tr>
<td>Waugh, David</td>
<td>Friends of the Cancer Centre</td>
<td>Infrastructure for NI Cancer Trials Centre</td>
<td>£900,000</td>
<td>01/09/13</td>
<td>31/08/16</td>
</tr>
<tr>
<td>Williams, Rich</td>
<td>Invest NI – PoC</td>
<td>Development of Inhaler based Cathespin S Inhibitor for treating COPD</td>
<td>£105,934</td>
<td>01/09/13</td>
<td>31/08/14</td>
</tr>
<tr>
<td>Wilson, Richard</td>
<td>Cancer Research UK</td>
<td>CTAAC grant A15828 for BALLAD trial (A Global Study To Evaluate The Potential Benefit Of Adjuvant Chemotherapy For Small Bowel Adenocarcinoma)</td>
<td>£613,167*</td>
<td>01/11/13</td>
<td>31/10/18</td>
</tr>
</tbody>
</table>


Welcome to the following new staff who have recently joined the Centre:

**Clinical Research Fellows:**
Dr Catherine Davidson

**Almac Seconded Staff:**
Dr Oliver Barker  
Mr Alan Brown  
Dr Frank Burkamp  
Dr Gerald Gawry  
Dr Peter Hewitt  
Dr Dominic Janssen  
Dr Linda Jordan  
Dr Keeva McClelland  
Mrs Mary McFarland  
Dr Hugues Miel  
Dr Colin O’Dowd  
Dr Krzysztofa Odrzywol  
Dr Natalie Page  
Dr Shane Rountree  
Dr Steven Shepherd  
Dr Andrea Valentine  
Dr Andrew Wilkinson

**Research Staff:**
Dr Hilary Colyer  
Dr El Habib Dakir  
Mr Joel Riley  
Dr Daniela Schmid

**Administrative/Clerical:**
Miss Jane Arbuthnot  
Miss Claire Atchison  
Ms Margaret Carr  
Miss Julie McClean

**Visiting Researchers:**
Ms Sara Fernandez  
Ms Siobhan Holden

**Honorary Staff:**
Dr Tim Davison  
Dr Ian Harley  
Dr Conor McGarry  
Dr Stuart McIntosh  
Dr Damian McManus  
Dr Declan O’Rourke  
Dr Giuseppe Schettino

---

**CCRCB EVENTS**

**Mitchell Lecture 2013/14**
20 February 2014 at 4.00pm  
CCRCB Building  
Professor Michael Stratton  
Wellcome Trust Sanger Institute

---

**EVENTS**

**Signalling and Acquired Resistance to Targeted Cancer Therapeutics**
5 – 7 January 2014  
Robinson College  
Cambridge, UK  
For further information and registration please refer to:  
http://www.biochemistry.org/Conferences.aspx

**ISREC Symposium: Metastatic colonization:**
Micro-environments, mechanisms and therapeutic targeting  
22 – 25 January 2014  
Crans Montana, Switzerland  
For further information and registration please refer to:  
http://isrec2014.epfl.ch/

**2nd EACR Conference on Cell Death in Cancer**
30 January – 1 February 2014  
De Rode Hotel  
Amsterdam, The Netherlands  
For further information and registration please refer to:  
http://www.eacr.org/celldeath2014/

**IACR 2014 Conference**
27 – 28 February 2014  
Galway Bay Hotel  
Galway, Ireland  
For further information and registration please refer to:  
http://www.ia-cr.ie/

**ASCO 50th Annual Meeting**
30 May – 3 June 2014  
McCormick Place  
Chicago, Illinois, USA  
For further information and registration please refer to:  
http://am.asco.org/

Comments on the CCRCB Bulletin or suggestions for future editions should be forwarded to katie.stewart@qub.ac.uk